Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
4-nitrocatechol sulfate + H2O
4-nitrocatechol + sulfate
cerebroside 3-sulfate + H2O
cerebroside + sulfate
cerebroside 3-sulphate + H2O
cerebroside + sulfate
the enzyme catalyzes the first step in the degradation of the glycolipid cerebroside sulfate
-
?
p-nitrocatechol sulfate + H2O
p-nitrocatechol + sulfate
-
-
?
sulfogalactosylceramide + H2O
?
sulfogalactosylglycerolipid + H2O
?
additional information
?
-
substrate binding and docking study, using crystal structures, PDB IDs 1N2K and 1E2S, overview
-
-
?
4-nitrocatechol sulfate + H2O
4-nitrocatechol + sulfate
-
-
-
?
4-nitrocatechol sulfate + H2O
4-nitrocatechol + sulfate
artificial substrate, Cys69 is the catalytic residue, and Lys302 and Lys123 act as residues anchoring the sulfate group to the active site, interaction with the enzyme active site, overview
-
-
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
-
-
-
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
-
-
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
-
-
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
-
-
-
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
-
galactosyl ceramid
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
-
galactosyl ceramide
-
?
cerebroside 3-sulfate + H2O
cerebroside + sulfate
the enzyme catalyzes the first step in the degradation of the glycolipid cerebroside sulfate. Accumulation of cerebroside sulfate is responsible for metachromatic leukodystrophy, a severe autosomal recessive inherited disorder. Good correlation between the type of mutation, deficient arylsulfatase A activity and disease severity is recognized
-
-
?
sulfogalactosylceramide + H2O
?
-
-
-
?
sulfogalactosylceramide + H2O
?
Cys69 is the catalytic residue, and Lys302 and Lys123 act as residues anchoring the sulfate group to the active site, interaction with the enzyme active site, overview
-
-
?
sulfogalactosylglycerolipid + H2O
?
-
-
-
?
sulfogalactosylglycerolipid + H2O
?
Cys69 is the catalytic residue, and Lys302 and Lys123 act as residues anchoring the sulfate group to the active site, interaction with the enzyme active site, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adrenoleukodystrophy
Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases.
arylsulfatase (type i) deficiency
Multiple sulfatase deficiency with a novel biochemical presentation.
arylsulfatase (type i) deficiency
Retinal pigment epithelial degeneration associated with leukocytic arylsulfatase A deficiency.
Breast Diseases
Evaluation of leukocyte arylsulfatase-A activity in patients with breast cancer and benign breast disease.
Breast Neoplasms
Evaluation of leukocyte arylsulfatase-A activity in patients with breast cancer and benign breast disease.
Cerebral Palsy
Kinetics and activity of arylsulfatase A in leukocytes derived from patients with cerebral palsy.
cerebroside-sulfatase deficiency
Complications in the genotypic molecular diagnosis of pseudo arylsulfatase A deficiency.
cerebroside-sulfatase deficiency
Deficient glycosylation of arylsulfatase A in pseudo arylsulfatase-A deficiency.
cerebroside-sulfatase deficiency
Metachromatic leukodystrophy: arylsulfatase-A deficiency in skin fibroblast cultures.
cerebroside-sulfatase deficiency
Pseudo arylsulfatase-A deficiency in healthy individuals: genetic and biochemical relationship to metachromatic leukodystrophy.
Cranial Nerve Diseases
Isolated cranial nerve enhancement in metachromatic leukodystrophy.
Demyelinating Diseases
Delayed postanoxic demyelination and arylsulfatase-A pseudodeficiency.
Gait Disorders, Neurologic
Isolated cranial nerve enhancement in metachromatic leukodystrophy.
Leukodystrophy, Globoid Cell
Late-onset Krabbe disease initially diagnosed as cerebroside sulfatase activator deficiency.
Leukodystrophy, Metachromatic
A correlation of intracellular cerebroside sulfatase activity in fibroblasts with latency in metachromatic leukodystrophy.
Leukodystrophy, Metachromatic
Adult metachromatic leukodystrophy. II. Ultrastructural findings in peripheral nerve and skeletal muscle.
Leukodystrophy, Metachromatic
An arylsulfatase A (ARSA) missense mutation (T274M) causing late-infantile metachromatic leukodystrophy.
Leukodystrophy, Metachromatic
Arylsulfatases A and B in EBV-transformed lymphoid cell lines: studies on their molecular forms in cells from patients with inborn sulfatase deficiencies. Comparative diagnostic value of enzymatic assays.
Leukodystrophy, Metachromatic
Autoreactivity to Sulfatide by Human Invariant NKT Cells.
Leukodystrophy, Metachromatic
Biochemical characterization of two (C300F, P425T) arylsulfatase a missense mutations.
Leukodystrophy, Metachromatic
Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy.
Leukodystrophy, Metachromatic
Cerebroside sulfatase activity in cultivated human skin fibroblasts and amniotic fluid cells;.
Leukodystrophy, Metachromatic
Correction of Brain Oligodendrocytes by AAVrh.10 Intracerebral Gene Therapy in Metachromatic Leukodystrophy Mice.
Leukodystrophy, Metachromatic
Deficient glycosylation of arylsulfatase A in pseudo arylsulfatase-A deficiency.
Leukodystrophy, Metachromatic
Diffuse-disseminated sclerosis combined with partial arylsulfatase A (ASA) deficiency. Mixed heterozygosity of ASA- and pseudo-ASA-deficiency?
Leukodystrophy, Metachromatic
Discussion: Metachromatic leukodystrophy, an unusual case with a subtle cerebroside sulfatase defect.
Leukodystrophy, Metachromatic
Genetic complementation in somatic cell hybrids of cerebroside sulfatase activator deficiency and metachromatic leukodystrophy fibroblasts.
Leukodystrophy, Metachromatic
Improved synthesis of [1-14C]acyl-sphingosine-galactose-3-sulfate (sulfatide) for diagnosis of metachromatic leukodystrophy: usefulness of radioscanning.
Leukodystrophy, Metachromatic
Late-Onset Metachromatic Leukodystrophy with Early Onset Dementia Associated with a Novel Missense Mutation in the Arylsulfatase A Gene.
Leukodystrophy, Metachromatic
Metachromatic leukodystrophy caused by a partial cerebroside sulfatase.
Leukodystrophy, Metachromatic
Metachromatic leukodystrophy. Diffusion MR imaging and proton MR spectroscopy.
Leukodystrophy, Metachromatic
Metachromatic leukodystrophy. Treatment with arylsulfatase-A.
Leukodystrophy, Metachromatic
Metachromatic leukodystrophy: arylsulfatase-A deficiency in skin fibroblast cultures.
Leukodystrophy, Metachromatic
Metachromatic leukodystrophy: molecular genetics and an animal model.
Leukodystrophy, Metachromatic
Molecular and clinical consequences of novel mutations in the arylsulfatase A gene.
Leukodystrophy, Metachromatic
Multiple sulfatase deficiency with a novel biochemical presentation.
Leukodystrophy, Metachromatic
Prenatal diagnosis of metachromatic leukodystrophy: a diagnosis by amniotic fluid and its confirmation.
Leukodystrophy, Metachromatic
Pseudo arylsulfatase-A deficiency in healthy individuals: genetic and biochemical relationship to metachromatic leukodystrophy.
Leukodystrophy, Metachromatic
Pseudodeficiency of arylsulphatase A: strategy for clarification of genotype in families of subjects with low ASA activity and neurological symptoms.
Leukodystrophy, Metachromatic
Retinal pigment epithelial degeneration associated with leukocytic arylsulfatase A deficiency.
Leukodystrophy, Metachromatic
The AB-variant of metachromatic leukodystrophy (postulated activator protein deficiency). Light and electron microscopic findings in a sural nerve biopsy.
Leukodystrophy, Metachromatic
Very low arylsulfatase A and cerebroside sulfatase activities in leukocytes of healthy members of metachromatic leukodystrophy family.
Leukodystrophy, Metachromatic
[Metachromatic leucodystrophy. Clinical, biological, and therapeutic aspects]
Leukodystrophy, Metachromatic
[Problems in the diagnosis of metachromatic leukodystrophy by arylsulfatase-A assay in white blood cells. Genetic study of normal enzyme values in 64 mother and child pairs (author's transl)]
Lysosomal Storage Diseases
Biochemical characterization of two (C300F, P425T) arylsulfatase a missense mutations.
Lysosomal Storage Diseases
Deficient glycosylation of arylsulfatase A in pseudo arylsulfatase-A deficiency.
Lysosomal Storage Diseases
[Metachromatic leucodystrophy. Clinical, biological, and therapeutic aspects]
Multiple Sclerosis
Brain galactolipid content in a patient with pseudoarylsulfatase A deficiency and coincidental diffuse disseminated sclerosis, and in patients with metachromatic, adreno-, and other leukodystrophies.
Multiple Sulfatase Deficiency Disease
Multiple sulfatase deficiency with a novel biochemical presentation.
Neoplasms
Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer.
Neurodegenerative Diseases
Pseudo arylsulfatase-A deficiency in healthy individuals: genetic and biochemical relationship to metachromatic leukodystrophy.
Urinary Bladder Neoplasms
Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
A212P
naturally occuring ARSA polymorphism, causes a severe peripheral neuropathy phenotype
A96G
mutation contributes to enzyme activity reduction
C168stop
naturally occuring ARSA polymorphism, causes a severe peripheral neuropathy phenotype
C493F
mutant shows 0.7% of wild type ARSA activity
C69A
The inactive mutant in complex with p-nitrocatechol sulfate mimics a reaction intermediate during sulfate ester hydrolysis by the active enzyme, without the covalent bond to the key side-chain C-alpha-formylglycine
D407fs
naturally occuring ARSA polymorphism, causes a severe peripheral neuropathy phenotype
E253K
mutation contributes to enzyme activity reduction
E253K/T391S
mutations contribute to sum of the enzyme activity reduction ascribed to each mutation
E307K
naturally occuring ARSA polymorphism, causes a mild peripheral neuropathy phenotype
G293C
mutant shows 0.5% of wild type ARSA activity
H138D
naturally occuring ARSA polymorphism, causes a mild peripheral neuropathy phenotype
H231Q
mutation identified in three patients belonging to a consanguineous family with late-infantile metachromatic leukodystrophy disorder MLD. The mutation leads to changes in the pre-mRNA secondary structure and in the ArsA protein structure
L52P
naturally occuring ARSA polymorphism, causes a severe peripheral neuropathy phenotype
N350S
mutation contributes to enzyme activity reduction
P426L
mutation contributes to enzyme activity reduction
P426L/N350S/96A>G
mutations contribute to sum of the enzyme activity reduction ascribed to each mutation
S406G
naturally occuring ARSA polymorphism, causes a severe peripheral neuropathy phenotype
T304M
naturally occuring ARSA polymorphism, causes a severe peripheral neuropathy phenotype
T391S
mutation contributes to enzyme activity reduction
C69S
the mutant is able to bind covalently to the substrate and hydrolyse it, but is unable to release the resulting sulfate
C69S
present at significantly higher levels in both conditioned media and within the cell when compared with wild type
additional information
study of disease-causing mutations, severe phenotype of this patient depends not only on the two disease-causing mutations, but also to some extent on the pseudodeficiency mutations
additional information
the frameshift mutations g.445_446dupG and g.2590_2591dupC are associated with metachromatic leukodystrophy and lead 0.3% or 10% of wild type ARSA activity, respectively
additional information
-
the frameshift mutations g.445_446dupG and g.2590_2591dupC are associated with metachromatic leukodystrophy and lead 0.3% or 10% of wild type ARSA activity, respectively
additional information
naturally occuring ARSA polymorphisms, overview
additional information
characterization of pathogenic variants c.98T > C, c.195delC, c.229G > C, c.545C > G, c.674A > G, c.852T > A, and c.1274A > G, which were found when sequencing a cohort of 31 German metachromatic leukodystrophy families. Upon expression in immortalized, human multipotent mesenchymal stromal cells prepared from a patient deficient in ARSA activity, the seven mutants show ARSA activity of less than 10% when compared with wild type
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Lukatela, G.; Krauss, N.; Theis, K.; Selmer, T.; Gieselmann, V.; von Figura, K.; Saenger, W.
Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis
Biochemistry
37
3654-3664
1998
Homo sapiens (P15289)
brenda
Vagedes, P.; Saenger, W.; Knapp, E.W.
Driving forces of protein association: the dimer-octamer equilibrium in arylsulfatase A
Biophys. J.
83
3066-3078
2002
Homo sapiens (P15289)
brenda
Regis, S.; Corsolini, F.; Stroppiano, M.; Cusano, R.; Filocamo, M.
Contribution of arylsulfatase A mutations located on the same allele to enzyme activity reduction and metachromatic leukodystrophy severity
Hum. Genet.
110
351-355
2002
Homo sapiens (P15289)
brenda
von Bulow, R.; Schmidt, B.; Dierks, T.; von Figura, K.; Uson, I.
Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis
J. Mol. Biol.
305
269-277
2001
Homo sapiens (P15289)
brenda
Christianson, T.M.; Starr, C.M.; Zankel, T.C.
Overexpression of inactive arylsulfatase mutants and in vitro activation by light-dependent oxidation with vanadate
Biochem. J.
382
581-587
2004
Homo sapiens (P15289)
brenda
Lugowska, A.; Wlodarski, P.; Ploski, R.; Mierzewska, H.; Dudzinska, M.; Matheisel, A.; Swietochowska, H.; Tylki-Szymanska, A.
Molecular and clinical consequences of novel mutations in the arylsulfatase A gene
Clin. Genet.
75
57-64
2009
Homo sapiens (P15289), Homo sapiens
brenda
Schenk, M.; Koppisetty, C.A.; Santos, D.C.; Carmona, E.; Bhatia, S.; Nyholm, P.G.; Tanphaichitr, N.
Interaction of arylsulfatase-A (ASA) with its natural sulfoglycolipid substrates: a computational and site-directed mutagenesis study
Glycoconj. J.
26
1029-1045
2009
Homo sapiens (P15289), Sus scrofa (Q8WNR3)
brenda
Cesani, M.; Capotondo, A.; Plati, T.; Sergi, L.S.; Fumagalli, F.; Roncarolo, M.G.; Naldini, L.; Comi, G.; Sessa, M.; Biffi, A.
Characterization of new arylsulfatase A gene mutations reinforces genotype-phenotype correlation in metachromatic leukodystrophy
Hum. Mutat.
30
E936-E945
2009
Homo sapiens (P15289)
brenda
Boehringer, J.; Santer, R.; Schumacher, N.; Gieseke, F.; Cornils, K.; Pechan, M.; Kustermann-Kuhn, B.; Handgretinger, R.; Schoels, L.; Harzer, K.; Kraegeloh-Mann, I.; Mueller, I.
Enzymatic characterization of novel arylsulfatase A variants using human arylsulfatase A-deficient immortalized mesenchymal stromal cells
Hum. Mutat.
38
1511-1520
2017
Homo sapiens (P15289)
brenda
Issa, A.B.; Feki, F.K.; Jdila, M.B.; Khabou, B.; Rhouma, B.B.; Ammar-Keskes, L.; Triki, C.; Fakhfakh, F.
Clinical, molecular, and computational analysis showed a novel homozygous mutation among the substrate-binding site of ARSA protein in consanguineous family with late-infantile MLD
J. Mol. Neurosci.
66
17-25
2018
Homo sapiens (P15289)
brenda